The level of open-market selling is minimal relative to company size and appears routine, possibly related to tax or portfolio management following equity vesting. Traders should not interpret this as a negative signal. Monitor for larger or sustained selling patterns.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 14 $578.54entry
- T+1 · 7mo ago −0.17%α −0.95% · $577.58
- T+5 · 7mo ago −0.88%α −2.26% · $573.46
- T+20 · 6mo ago +0.55%α −5.74% · $581.74
- T+60 · 4mo ago −5.44%α −14.15% · $547.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three United Therapeutics insiders, including the CEO and CFO, conducted open-market share sales totaling $158K over a 7-day period, concurrent with derivative exercises. The open-market selling is modest in magnitude relative to the company's $25.3B market cap.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold $271K worth of shares in two transactions ($20K on 2026-04-13 and $251K on 2026-04-10), but only $20K is from open-market selling; the rest stems from derivative exercises.
- EVP Paul Mahon sold $115K in open-market shares, following derivative exercises of 8,300 shares.
- CFO James Edgemond sold $23K in open-market shares, alongside derivative exercises of 20,000 shares.
- Total open-market selling by insiders: $158K over 7 days.
- All open-market sales represent less than 0.001% of United Therapeutics' $25.3B market cap.
Financial Impact
$158,000 in open-market selling over 7 days (<0.001% of market cap)
Risk Factors
- Perception risk if media mischaracterizes derivative exercises as insider selling.
- Potential for increased scrutiny if future filings show accelerating open-market dispositions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1776371482368 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers